Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 10/20 | 0.64 |
| ▸ | AKR1C2 | P52895 | 10/20 | 0.64 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30730198 | 1.00 | AKR1C3 (0.64) | AKR1C3AKR1C2AKR1C1PTGS1KCNQ2 | |
| SCHEMBL6017403 | 1.00 | AKR1C3 (0.64) | AKR1C3AKR1C2AKR1C1PTGS1KCNQ2 | |
| SCHEMBL9242973 | 0.88 | AKR1C3 (0.64) | AKR1C3AKR1C2AKR1C1PTGS1 | |
| SCHEMBL11192581 | 0.86 | AKR1C3 (0.54) | AKR1C3AKR1C2AKR1C1PTGS1 | |
| SCHEMBL585600 | 0.86 | AKR1C3 (0.54) | AKR1C3AKR1C2AKR1C1PTGS1KCNQ2 | |
| SCHEMBL9063835 | 0.86 | AKR1C3 (0.51) | AKR1C3AKR1C2AKR1C1PTGS1KCNQ2 | |
| SCHEMBL1590616 | 0.85 | AKR1C3 (0.50) | AKR1C3AKR1C2AKR1C1PTGS1KCNQ2 | |
| SCHEMBL22230559 | 0.85 | AKR1C3 (0.56) | AKR1C3AKR1C2AKR1C1PTGS1 | |
| SCHEMBL9064210 | 0.82 | AKR1C3 (0.48) | AKR1C3AKR1C2AKR1C1PTGS1 | |
| SCHEMBL4914159 | 0.82 | AKR1C3 (0.48) | AKR1C3AKR1C2AKR1C1PTGS1KCNQ2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080124402-A1 | N-(Pyridin-3-Yl)-2-Phenylbutanamides As Androgen Receptor Modulators | MERCK & CO., INC. (US) | 2008-05-29 | — | — | US | disclosed |
| US-20080124402-A1 | N-(Pyridin-3-Yl)-2-Phenylbutanamides As Androgen Receptor Modulators | MERCK & CO., INC. (US) | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080124402-A1 | N-(Pyridin-3-Yl)-2-Phenylbutanamides As Androgen Receptor Modulators | SHBG, AR, NR5A1 | AKR1C3 328/4885AKR1C2 504/4885AKR1C1 663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.